Meeting
2019 ASCO Annual Meeting
Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).
Authors
Akash Mukherjee
The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX
Akash Mukherjee , Denai R. Milton , Elias Jabbour , Alison Gulbis , Tapan M. Kadia , Philip A. Thompson , Michael J. Keating , Nitin Jain , Celina Ledesma , Luis Fayad , Loretta J. Nastoupil , Jan Andreas Burger , Alessandra Ferrajoli , Zeev Estrov , Hagop M. Kantarjian , Richard E. Champlin , Issa F. Khouri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7550)
DOI
10.1200/JCO.2019.37.15_suppl.7550
Abstract #
7550
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
First Author: Paul M. Barr
Poster
2023 ASCO Annual Meeting
Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.
First Author: Richard Mcshinsky
Poster
2023 ASCO Annual Meeting
BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
First Author: George Follows
Poster
2023 ASCO Annual Meeting
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
First Author: Ömür Gökmen Sevindik